Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF β and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
ConclusionsBintrafusp alfa demonstrated a manageable safety profile and efficacy in Asian patients with pretreated esophageal SCC.Clinical Trials RegistrationNCT02699515.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Esophagus Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology